Opus Genetics (IRD) Depreciation & Amortization (CF) (2010 - 2026)
Opus Genetics (IRD) reported Depreciation & Amortization (CF) of $13000.0 for Q1 2026, little changed year-over-year from $13000.0 in Q1 2025, and little changed quarter-over-quarter from $13000.0 in Q4 2025.
Opus Genetics (IRD) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $13000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $13000.0, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $53000.0 (up 130.43% YoY), and the FY2025 annual result was $53000.0, up 430.0% from the prior year.
- Depreciation & Amortization (CF) held at $13000.0 in Q1 2026 per IRD's latest filing, from $13000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $14000.0 in Q2 2025 and troughed at $1000.0 in Q1 2022.
- A 5-year average of $6142.9 and a median of $2000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) changed 0.0% in 2022, then surged 233.33% in 2024.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $1000.0 in 2022, then jumped by 200.0% to $3000.0 in 2023, then surged by 233.33% to $10000.0 in 2024, then grew by 30.0% to $13000.0 in 2025, then changed by 0.0% to $13000.0 in 2026.
- Business Quant data shows IRD's Depreciation & Amortization (CF) at $13000.0 in Q1 2026, $13000.0 in Q4 2025, and $13000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Opus Genetics | 355.39 Mn | 295.43 Mn | - | 13,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13,000.00 |
| Mar 31, 2026 | 13,000.00 |
| Dec 31, 2025 | 13,000.00 |
| Dec 31, 2025 | 13,000.00 |
| Sep 30, 2025 | 13,000.00 |
| Sep 30, 2025 | 13,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Mar 31, 2025 | 13,000.00 |
| Mar 31, 2025 | 13,000.00 |
| Dec 31, 2024 | 10,000.00 |
| Dec 31, 2024 | 10,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 1,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Mar 31, 2023 | 1,000.00 |